HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial ...

Until recently, uveal melanoma was a disease that ... approved by the FDA for eligible adults with uveal melanoma and unresectable liver metastases. The European vs the US situation In Europe ...

The updated NCCN Guidelines now include HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant uveal melanoma. Previously, the guidelines limited its use to patients with ...

Given that over 90% of mUM patients develop liver metastases ... role hepatic progression plays in the course of metastatic uveal melanoma,” said Gerard Michel, Chief Executive Officer of ...

HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of ...

Reports Q4 revenue $15.1M, consensus $14.96M. “In 2024, the successful launch of HEPZATO drove strong financial and operational results, ...

The global uveal melanoma treatment market is projected ... believe it or not, would be the liver. The cancer itself comes about downstream from the Protein Kinase, which functions downstream ...

Q4 2024 Earnings Call Transcript March 6, 2025 Delcath Systems, Inc. beats earnings expectations. Reported EPS is $0.05, ...

Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...